Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. (Q37376742)
Jump to navigation
Jump to search
scientific article published on March 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa. |
scientific article published on March 2013 |
Statements
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosa (English)
Thomas J Conlon
Kirsten Erger
Travis Cossette
Ji-jing Pang
Renee Ryals
Nathalie Clément
Brian Cleaver
Issam McDoom
Shannon E Boye
Marc C Peden
Mark B Sherwood
Corinne R Abernathy
Sanford L Boye